Please assess the completion status of the following clinical trial:

Trial Title: A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability and willingness to provide written informed consent and adhere to study regimen~* Recipients who are 18-70 years of age~* Patients who have undergone either single or double lung transplant are discharged on the standard MMF (no generic MMF will be used) therapy and complain of GI symptoms, thought to be related to their immunosuppressive regimen~Exclusion Criteria:~* Patients who have GI complaints thought to be due to factors other than immunosuppressive regimen~* Patients receiving steroid treatment for acute rejection~* Women of childbearing potential who do not agree to use at least two acceptable forms of contraception prior to starting study drug, while taking study drug, and for 6 weeks after stopping study drug~* Women who have a positive serum or urine pregnancy test at visit 1 and/or continuing through the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Patients taking Myfortic (Type: OTHER): Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).